Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From the Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept <scp>AFFINITY</scp> Study

Although the primary endpoint was not achieved, secondary endpoints and exploratory analyses suggest that participants with TNFi-IR PsA, particularly those with elevated CRP, could derive clinically meaningful benefits with guselkumab+golimumab combination therapy, with no new safety concerns, warranting further investigation.